Who are Biomatrix drug eluting stent's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Drug-eluting Stent Mometasone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/biomatrix-drug-eluting-stent.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Biomatrix drug eluting stent — Competitive Intelligence Brief

Biomatrix drug eluting stent (Biomatrix drug eluting stent) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Drug-eluting stent. Area: Cardiovascular.

marketed Drug-eluting stent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Biomatrix drug eluting stent (Biomatrix drug eluting stent) — Seoul National University Bundang Hospital. A drug-eluting stent that releases an active pharmaceutical agent to prevent restenosis (re-narrowing) of coronary arteries after angioplasty.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Biomatrix drug eluting stent TARGET	Biomatrix drug eluting stent	Seoul National University Bundang Hospital	marketed	Drug-eluting stent
Drug-eluting Stent Mometasone	Drug-eluting Stent Mometasone	Children's Hospital Medical Center, Cincinnati	marketed	Drug-eluting stent (corticosteroid-eluting)	Glucocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Drug-eluting stent class)

Seoul National University Bundang Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Biomatrix drug eluting stent — Competitive Intelligence Brief. https://druglandscape.com/ci/biomatrix-drug-eluting-stent. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab